Epithelial-mesenchymal transition in development and cancer
- PMID: 19852726
- DOI: 10.2217/fon.09.94
Epithelial-mesenchymal transition in development and cancer
Abstract
The epithelial-mesenchymal transition (EMT) is a critical developmental process from the earliest events of embryogenesis to later morphogenesis and organ formation. EMT contributes to the complex architecture of the embryo by permitting the progression of embryogenesis from a simple single-cell layer epithelium to a complex three-dimensional organism composed of both epithelial and mesenchymal cells. However, in most tissues EMT is a developmentally restricted process and fully differentiated epithelia typically maintain their epithelial phenotype. Recently, elements of EMT, specifically the loss of epithelial markers and the gain of mesenchymal markers, have been observed in pathological states, including epithelial cancers. Analysis of the molecular mechanisms of this oncogenic epithelial plasticity have implicated the inappropriate expression and activation of developmental EMT programs, suggesting that cancer cells may reinstitute properties of developmental EMT including enhanced migration and invasion. Thus, in the context of cancer, an EMT-like process may permit dissemination of tumor cells from the primary tumor into the surrounding stroma, setting the stage for metastatic spread. Consistent with this hypothesis, activation of these developmental EMT programs in human cancer correlates with advanced disease and poor prognosis. This review will focus on the current knowledge regarding developmental EMT pathways that have been implicated in cancer progression.
Similar articles
-
[Epithelial-mesenchymal transitions in cancer onset and progression].Bull Acad Natl Med. 2009 Dec;193(9):1969-78; discussion 1978-9. Bull Acad Natl Med. 2009. PMID: 20666011 French.
-
Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Epub 2008 Aug 20. Drug Resist Updat. 2008. PMID: 18718806 Review.
-
[Epithelial-mesenchymal transition in cancer progression].Postepy Biochem. 2009;55(2):121-8. Postepy Biochem. 2009. PMID: 19824467 Review. Polish.
-
Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.Cells Tissues Organs. 2007;185(1-3):85-94. doi: 10.1159/000101307. Cells Tissues Organs. 2007. PMID: 17587812 Review.
-
Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer.Asian Pac J Cancer Prev. 2013;14(5):2689-98. doi: 10.7314/apjcp.2013.14.5.2689. Asian Pac J Cancer Prev. 2013. PMID: 23803016 Review.
Cited by
-
KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.Sci Transl Med. 2013 Jan 23;5(169):169ra12. doi: 10.1126/scitranslmed.3004688. Sci Transl Med. 2013. PMID: 23345610 Free PMC article.
-
Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ.Int J Surg Oncol. 2012;2012:984346. doi: 10.1155/2012/984346. Epub 2012 Apr 2. Int J Surg Oncol. 2012. PMID: 22577534 Free PMC article.
-
NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition.Oncogene. 2016 Apr 28;35(17):2266-78. doi: 10.1038/onc.2015.289. Epub 2015 Aug 10. Oncogene. 2016. PMID: 26257059 Free PMC article.
-
Transforming growth factor-β1 treatment of oral cancer induces epithelial-mesenchymal transition and promotes bone invasion via enhanced activity of osteoclasts.Clin Exp Metastasis. 2013 Jun;30(5):659-70. doi: 10.1007/s10585-013-9570-0. Epub 2013 Feb 2. Clin Exp Metastasis. 2013. PMID: 23378237 Free PMC article.
-
Immune microenvironment in tumor progression: characteristics and challenges for therapy.J Oncol. 2012;2012:608406. doi: 10.1155/2012/608406. Epub 2012 Aug 8. J Oncol. 2012. PMID: 22927846 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources